Pair Name | Amygdalin, Cisplatin | ||
Phytochemical Name | Amygdalin (PubChem CID: 656516 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Amygdalin, Cisplatin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BBC3 | hsa27113 | |
Up-regulation | Expression | BCL2 | hsa596 | |
Up-regulation | Expression | BCL-xL | hsa598 | |
Down-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Phosphorylation | TP53 | hsa7157 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 | |
Result | Our present findings suggest that amygdalin has chemo-modulatory effect when used in co-treatment with cisplatin and is able to protect normal breast cells as well as the fibroblasts during chemotherapy treatment, indicating a strong selective chemoprotective ability and may contribute to a better quality of life for cancer patients. |
No. | Title | Href |
---|---|---|
1 | Amygdalin as a chemoprotective agent in co-treatment with cisplatin. Front Pharmacol. 2022 Sep 20;13:1013692. doi: 10.3389/fphar.2022.1013692. | Click |